| CTIGX | RPTIX | CTIGX / RPTIX | |
| Total Expense Ratio | 1.10 | 0.63 | 175% |
| Annual Report Gross Expense Ratio | 1.56 | 0.63 | 248% |
| Fund Existence | 6 years | 10 years | - |
| Gain YTD | 19.907 | 3.369 | 591% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 1000000 | 500000 | 200% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 37.5M | 25.9B | 0% |
| Annual Yield % from dividends | 2.19 | 0.05 | 4,297% |
| Returns for 1 year | 13.12 | -8.70 | -151% |
| Returns for 3 years | 86.22 | 10.44 | 826% |
| Returns for 5 years | 41.01 | -6.04 | -679% |
| Returns for 10 years | N/A | 31.48 | - |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AMDG | 45.02 | 6.83 | +17.88% |
| Leverage Shares 2X Long AMD Daily ETF | |||
| HQL | 16.98 | 0.22 | +1.31% |
| abrdn Life Sciences Investors | |||
| BTA | 9.56 | 0.01 | +0.10% |
| Blackrock Long-Term Municipal Advantage Trust | |||
| JMST | 50.92 | 0.01 | +0.02% |
| JPMorgan Ultra-Short Municipal Inc ETF | |||
| HELX | 34.90 | N/A | N/A |
| Franklin Genomic Advancements ETF | |||